IPL 423323

Drug Profile

IPL 423323

Alternative Names: IPL 400; IPL 4323; Sortac

Latest Information Update: 26 Feb 2003

Price : $50

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class
  • Mechanism of Action Phosphotransferase stimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 26 Feb 2003 No development reported - Preclinical for Transplant rejection in Canada (unspecified route)
  • 26 Feb 2003 No development reported - Preclinical for Psoriasis in Canada (unspecified route)
  • 07 Feb 2000 IPL 423323 is available for licensing (http://www.inflazyme.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top